Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 4/20 | 0.32 |
| ▸ | EPOR | P19235 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647116 | 0.89 | HSD17B10 (0.36) | POLBHSD17B10CYP3A4CYP2C19 | |
| SCHEMBL13686094 | 0.89 | HSD17B10 (0.36) | POLBHSD17B10CYP3A4CYP2C19 | |
| SCHEMBL13783671 | 0.89 | GLP1R (0.40) | GLP1RPOLBHSD17B10MGLLCYP3A4 | |
| SCHEMBL16507721 | 0.89 | GLP1R (0.40) | GLP1RPOLBHSD17B10MGLLCYP3A4 | |
| SCHEMBL16507765 | 0.89 | GLP1R (0.35) | GLP1RPOLBHSD17B10MGLLPLK1 | |
| SCHEMBL13889280 | 0.87 | GLP1R (0.39) | GLP1RPOLBHSD17B10MGLLCYP3A4 | |
| SCHEMBL10054214 | 0.85 | GLP1R (0.37) | GLP1RMGLLPLK1EPOR | |
| SCHEMBL16507748 | 0.85 | GLP1R (0.37) | GLP1RMGLLPLK1EPOR | |
| SCHEMBL14423081 | 0.84 | PLK1 (0.37) | GLP1RPLK1 | |
| SCHEMBL12409384 | 0.83 | GLP1R (0.39) | GLP1RPOLBHSD17B10MGLLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | CONJUCHEM, LLC | 2009-04-09 | — | — | US | disclosed |
| US-20090075890-A1 | Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof | CONJUCHEM BIOTECHNOLOGIES INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075890-A1 | Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof | IAPP, VIP, GLP1R | GLP1R 3/4885POLB 4528/4885HSD17B10 4312/4885 |
| US-20090093408-A1 | Protection of exendin-4 peptides through conjugation | VIP, PEPD, ANPEP | GLP1R 32/4885POLB 4246/4885HSD17B10 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.